Skip to main content

#156533

Anti-W6/1 [W6/1]

Cat. #156533

Anti-W6/1 [W6/1]

Cat. #: 156533

Unit size: 100 ug

Availability: 10-12 weeks

Target: Human erythrocytes of groups A1 and A2

Class: Monoclonal

Reactivity: Human

Host: Mouse

£300.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Institute: Medical Research Council; University of Oxford

Tool Details
Target Details
Handling
References

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

  • Name: Anti-W6/1 [W6/1]
  • Class: Monoclonal
  • Conjugation: Unconjugated
  • Reactivity: Human
  • Host: Mouse
  • Description: The W6/1 hybridoma cell line secretes monoclonal IgM antibodies reactive with a polymorphic determinant of human erythrocytes which correlated with blood group A. Application: human erythrocyte marker. Binds human erythrocytes of groups A1 and A2 but not group O and B.
  • Immunogen: Human tonsil membrane
  • Recommended controls: IgM

Target Details

  • Target: Human erythrocytes of groups A1 and A2
  • Target background: The W6/1 hybridoma cell line secretes monoclonal IgM antibodies reactive with a polymorphic determinant of human erythrocytes which correlated with blood group A. Application: human erythrocyte marker. Binds human erythrocytes of groups A1 and A2 but not group O and B.

Handling

  • Format: Liquid
  • Unit size: 100 ug
  • Shipping conditions: Dry ice

References

  • Barnstable et al. 1978. Cell. 14(1):9-20. PMID: 667938.

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.